Document:

Exhibit 10.20

 

BioRestorative Therapies, Inc.

40 Marcus Drive, Suite One

Melville, New York 11747

 

March 9, 2015

 

Mr. Francisco Silva

10 Flyers Lane

Tustin, California 92782

 

Dear Mr. Silva:

 

Reference is made to the
Amended and Restated Executive Employment Agreement, dated as of May 10, 2011, between BioRestorative Therapies, Inc. (formerly
known as Stem Cell Assurance, Inc.) (the “Company”) and you (the “Employee”), as amended (the “Employment
Agreement”).

 

The parties hereby agree
that, effective as of January 1, 2015, (i) the “Per Annum Salary” in Schedule A of the Employment Agreement is amended
to read as follows: “Per Annum Salary: $250,000”; (ii) the Employee shall be entitled to receive an annual bonus of
up to 20% of his Per Annum Salary based upon the satisfaction of certain performance goals and that the performance goals for the
year ended December 31, 2015, and the bonus amount payable with respect thereto, are as set forth on Schedule A attached hereto;
and (iii) the “Cash Severance Amount” in Schedule A of the Employment Agreement is amended to read as follows: “Cash
Severance Amount: Fifty percent (50%) of Per Annum Salary.”

 

Except as amended hereby,
the Employment Agreement shall continue in full force and effect in accordance with its terms.

 

	 	Very truly yours,
	 	 	 
	 	BioRestorative Therapies, Inc. 
	 	 	 
	 	By: 	     
	 	 	Mark Weinreb, Chief Executive Officer

 

Agreed:

 

	 	 
	Francisco Silva	 

 

    	 

    	 

    

 

SCHEDULE A

 

2015 Bonus Milestones:

 

		·	$7,500 in the event that, as a direct
result of the Employee’s efforts, the Company has an article published by a peer-reviewed journal with regard to its brtxDISCTM
or ThermoStem® program (or any future Company program);

 

		·	$10,000 in the event, as a direct result
of the Employee’s efforts, the Company enters into an agreement with an industrial strategic partner that, in the opinion
of the Company, considerably advances Company programs, it being understood that the Company may reject any and all proposed agreements
with regard thereto for any reason whatsoever;

 

		·	$7,500 in the event that, as a direct
result of the Employee’s efforts, the Company enters into an agreement with respect to a collaborative relationship with
an academic or institute within the New York metropolitan area that, in the opinion of the Company, results in the advancement
of the Company’s programs, it being understood that the Company may reject any and all proposed agreements with regard thereto
for any reason whatsoever;

 

		·	$25,000 in the event the Food and Drug
Administration approves an IND application with regard to the commencement of a clinical trial for a Company program.

 

Any issue as to whether any of the foregoing
conditions have been satisfied shall be determined by the Company in its sole discretion.Exhibit 10.58

 

BioRestorative Therapies, Inc.

40 Marcus Drive, Suite 1

Melville, New York 11747

 

February 11, 2015

 

Rohto Pharmaceutical Co., Ltd

1-8-1, Tatsumi-nishi, Ikuno-ku,

Osaka 544-8666, Japan

 

Gentlemen:

 

Reference is made to the Research and
Development Agreement, dated as of March 19, 2014 (the “Agreement”), between BioRestorative Therapies, Inc. (“BRT”)
and Rohto Pharmaceutical Co., Ltd. (“Rohto”). All capitalized terms used but not defined herein shall have the meanings
ascribed thereto in the Agreement.

 

The Parties acknowledge and agree that
the Term of the Agreement currently expires on March 19, 2015 and that additional time is needed for BRT to deliver the Final Report
to Rohto.

 

Accordingly, the Parties hereby agree
that Section 4.01 of the Agreement is amended to read as follows:

 

“4.01     Term.    This Agreement
shall commence as of the Effective Date and, unless sooner terminated or extended as provided hereunder, shall end on June 19,
2015 (the "Term"). The Term and the scope of this Agreement may be extended and expanded by mutual written agreement.”

 

Except as amended hereby, the Agreement
shall continue in full force and effect in accordance with its terms.

 

This letter may be executed in counterparts,
each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument.

 

This letter shall be governed by, and
construed in accordance with, the laws of the State of New York, excluding choice of law principles thereof.

 

Signatures hereon which
are transmitted via facsimile or email shall be deemed original signatures.

 

	 	Very truly yours,
	 	 	 
	 	BIORESTORATIVE THERAPIES, INC.
	 	 	 
	 	By:	 
	 	 	Mark Weinreb, Chief Executive Officer

 

Agreed:

 

ROHTO PHARMACEUTICAL CO., LTD.

 

	By:Exhibit 10.65

 

STOCK OPTION AGREEMENT,
made as of the 23rd day of October, 2014, between BIORESTORATIVE THERAPIES, INC., a Nevada corporation (the “Company”),
and Mark weinreb (the “Optionee”).

 

 

 

WHEREAS, the Optionee
serves as the Chief Executive Officer and Chairman of the Board of the Company; and

 

WHEREAS, the Company
desires to provide to the Optionee an additional incentive to promote the success of the Company.

 

NOW, THEREFORE,
in consideration of the foregoing, the Company hereby grants to the Optionee the right and option to purchase shares of Common
Stock of the Company under and pursuant to the terms and conditions of the Company’s 2010 Equity Participation Plan (the
“Plan”) and upon and subject to the following terms and conditions:

 

1.          GRANT
OF OPTION. The Company hereby grants to the Optionee the right and option (the “Option”) to purchase up to
Three Million (3,000,000) shares of Common Stock of the Company (the “Option Shares”) during the following periods:

 

(a)          All
or any part of One Million (1,000,000) shares of Common Stock may be purchased during the period commencing at 12:01 A.M. on October
23, 2015 and terminating at 5:00 P.M. on October 23, 2024 (the “Expiration Date”).

 

(b)          All
or any part of One Million (1,000,000) shares of Common Stock may be purchased during the period commencing at 12:01 A.M on October
23, 2016 and terminating at 5:00 P.M. on the Expiration Date.

 

(c)          All
or any part of One Million (1,000,000) shares of Common Stock may be purchased during the period commencing at 12:01 A.M on October
23, 2017 and terminating at 5:00 P.M. on the Expiration Date.

 

Notwithstanding the foregoing,
in the event that the Optionee’s employment with the Company is terminated by the Company without “cause” (as
such term is defined in the Employment Agreement, dated as of October 4, 2010, between the Company and the Optionee, as amended
(the “Employment Agreement”)) or by the Optionee for “Good Reason” (as such term is defined in the Employment
Agreement), or, in the event of a Change of Control (as such term is defined in the Employment Agreement), and, on the date of
termination of employment or any Change of Control, any portion of the Option is not exercisable, such unexercisable portion of
the Option shall become exercisable (an “Option Acceleration Event”).

 

2.          NATURE
OF OPTION. The Option is not intended to meet the requirements of Section 422 of the Internal Revenue Code of 1986, as
amended, relating to “incentive stock options”.

 

    	 

    	 

    

  

3.          EXERCISE
PRICE. The exercise price of each of the Option Shares shall be Thirty-Three Cents ($0.33) (the “Exercise Price”).
The Company shall pay all original issue or transfer taxes on the exercise of the Option.

 

4.          EXERCISE
OF OPTIONS. (a) The Option shall be exercised in accordance with the provisions of the Plan. As soon as practicable after
the receipt of notice of exercise and payment of the Exercise Price as provided for in the Plan, the Company shall tender to the
Optionee a certificate issued in the Optionee’s name evidencing the number of Option Shares covered thereby.

 

(b)          The
Company agrees that, as contemplated in Section 13(b) of the Plan, the Optionee may elect to have the Company reduce the number
of Option Shares otherwise issuable by a number of Option Shares having a Fair Market Value (as defined in the Plan) equal to the
exercise price of the Option being exercised. In the event of such election, the Company shall issue to the Optionee a number of
Option Shares computed using the following formula:

 

	            X	=	Y (A-B)
	 	 	 A
	 	 	 
	Where X	=	the number of Option Shares to be issued to the Optionee
	 	 	 
	            Y	=	the number of Option Shares subject to this Option (or the portion thereof
    being cancelled) 
	 	 	 
	            A	=	the Fair Market Value of one Option Share
	 	 	 
	            B	=	the Exercise Price

 

5.          TRANSFERABILITY.
The Option shall not be transferable other than by will or the laws of descent and distribution and, during the Optionee’s
lifetime, shall not be exercisable by any person other than the Optionee.

 

6.          TERMINATION
OF EMPLOYMENT. To the extent the Option becomes exercisable, the Option shall remain exercisable until the Expiration Date
notwithstanding any subsequent termination of employment with the Company or its subsidiaries for any reason whatsoever. In addition,
in the event of an Option Acceleration Event, the Option shall remain exercisable until the Expiration Date notwithstanding any
termination of employment with the Company or its subsidiaries for any reason whatsoever.

 

7.          INCORPORATION
BY REFERENCE. The terms and conditions of the Plan are hereby incorporated by reference and made a part hereof.

 

    	2

    	 

    

  

8.          NOTICES.
Any notice or other communication given hereunder shall be deemed sufficient if in writing and hand delivered or sent by registered
or certified mail, return receipt requested, addressed to the Company, 555 Heritage Drive, Suite 132, Jupiter, Florida 33458, Attention:
Vice President of Operations, and to the Optionee at the address indicated below. Notices shall be deemed to have been given on
the date of hand delivery or mailing, except notices of change of address, which shall be deemed to have been given when received.

 

9.          BINDING
EFFECT. This Stock Option Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
legal representatives, successors and assigns.

 

10.         ENTIRE
AGREEMENT. This Stock Option Agreement, together with the Plan, contains the entire understanding of the parties hereto
with respect to the subject matter hereof and may be modified only by an instrument executed by the party sought to be charged.

 

11.         GOVERNING
LAW. This Stock Option Agreement shall be governed by, and construed in accordance with, the laws of the State of Nevada,
excluding choice of law rules thereof.

 

12.         EXECUTION
IN COUNTERPARTS. This Stock Option Agreement may be executed in counterparts, each of which shall be deemed to be an original,
but both of which together shall constitute one and the same instrument.

 

13.         FACSIMILE
SIGNATURES. Signatures hereon which are transmitted via facsimile, or other electronic image, shall be deemed original
signatures.

 

14.         INTERPRETATION;
HEADINGS. The provisions of this Stock Option Agreement shall be interpreted in a reasonable manner to give effect to the
intent of the parties hereto. The headings and captions under sections and paragraphs of this Stock Option Agreement are for convenience
of reference only and do not in any way modify, interpret or construe the intent of the parties or affect any of the provisions
of this Stock Option Agreement.

 

[Remainder of page
intentionally left blank; signature page follows]

 

    	3

    	 

    

  

IN WITNESS WHEREOF, the
parties have executed this Stock Option Agreement as of the day and year first above written.

 

	 	BIORESTORATIVE THERAPIES, INC.
	 	 	 
	 	By:	 
	 	 	Name: Mandy Clyde
	 	 	Title: Vice President of Operations
	 	 	 
	 	 	 
	 	 	Signature of Optionee
	 	 	 
	 	 	Mark Weinreb
	 	 	Name of Optionee 
	 	 	 
	 	 	 
	 	 	Address of Optionee

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]